118 related articles for article (PubMed ID: 2028237)
1. [Profibrinolytic activity of recombinant hirudin?].
Tsakiris DA; Meyer D; Fabbri J; Close P; Marbet GA
Schweiz Med Wochenschr; 1991 Mar; 121(10):338-40. PubMed ID: 2028237
[TBL] [Abstract][Full Text] [Related]
2. [Effect and mechanism of recombinant hirudin on fibrinolysis].
Li M; Zhang RJ; Cao GX; Wan WX; Zhang LF; Jin J
Yao Xue Xue Bao; 2006 Sep; 41(9):814-8. PubMed ID: 17111825
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.
Mirshahi M; Soria J; Soria C; Faivre R; Lu H; Courtney M; Roitsch C; Tripier D; Caen JP
Blood; 1989 Aug; 74(3):1025-30. PubMed ID: 2502207
[TBL] [Abstract][Full Text] [Related]
5. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma.
Gallistl S; Muntean W; Leis HJ
Thromb Haemost; 1995 Oct; 74(4):1163-8. PubMed ID: 8560429
[TBL] [Abstract][Full Text] [Related]
6. Effect of hirudin on tissue plasminogen activator induced clot lysis.
Electricwala A; Atkinson T
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):267-71. PubMed ID: 2129413
[TBL] [Abstract][Full Text] [Related]
7. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
8. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
9. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
[TBL] [Abstract][Full Text] [Related]
11. Hirudin in renal insufficiency.
Fischer KG
Semin Thromb Hemost; 2002 Oct; 28(5):467-82. PubMed ID: 12420243
[TBL] [Abstract][Full Text] [Related]
12. Recombinant desulfatohirudin as a substitute for heparin during cardiopulmonary bypass.
Bernabei A; Rao AK; Niewiarowski S; Colman RW; Sun L; Edmunds LH
J Thorac Cardiovasc Surg; 1994 Aug; 108(2):381-2. PubMed ID: 8041187
[No Abstract] [Full Text] [Related]
13. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
14. Optimizing management of hirudin anticoagulation.
Measday MA; Zucker ML; Pan CM; LaDuca FM
J Extra Corpor Technol; 2005 Mar; 37(1):66-70. PubMed ID: 15804161
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
16. Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin.
Ren K; Gong H; Hu L; He K; Yu A; Hu S; Liang S; Zhou C; Wu C
J Thromb Thrombolysis; 2021 Oct; 52(3):880-888. PubMed ID: 33826053
[TBL] [Abstract][Full Text] [Related]
17. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
[TBL] [Abstract][Full Text] [Related]
18. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
[TBL] [Abstract][Full Text] [Related]
19. Hirudin in heparin-induced thrombocytopenia.
Lubenow N; Greinacher A
Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.
Marbet GA; Verstraete M; Kienast J; Graf P; Hoet B; Tsakiris DA; Silling-Engelhardt G; Close P
J Cardiovasc Pharmacol; 1993 Sep; 22(3):364-72. PubMed ID: 7504125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
